Trends in the Use of Neoadjuvant Systemic Therapy for Head and Neck Squamous Cell Carcinoma
In this retrospective cohort study of HNSCC, rates of neoadjuvant immunotherapy nearly doubled between 2013 and 2022, whereas neoadjuvant chemotherapy use significantly decreased from 2007 to 2022. These trends highlight the evolving therapeutic landscape for HNSCC and provide context for emerging data on neoadjuvant therapy.
Authors
- Kevin J. Contrera (ORCID: https://orcid.org/0000-0002-2570-1706)
- Wesley L. Cai (ORCID: https://orcid.org/0000-0002-3871-5509)
- Dan Paul Zandberg (ORCID: https://orcid.org/0000-0002-1002-8301)
- Katie M. Carlson (ORCID: https://orcid.org/0009-0001-4807-6173)
- Angela L. Mazul (ORCID: https://orcid.org/0000-0002-1249-4613)
- José P. Zevallos (ORCID: https://orcid.org/0000-0002-9111-6767)
- Matthew E. Spector (ORCID: https://orcid.org/0000-0001-7646-6075)
- Robert L. Ferris (ORCID: https://orcid.org/0000-0001-6605-2071)
- Vanessa Helou (ORCID: https://orcid.org/0000-0003-4826-1659)
Institutions
- University of North Carolina Health Care (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.39778
- Citations
- 1
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.85